DOJOLVI® (triheptanoin) for LC-FAOD — Bazewp

← Back to Home

DOJOLVI® (triheptanoin) for LC-FAOD

dojolvi.com 🇺🇸 EN-US

DOJOLVI® (triheptanoin) is the first and only FDA-approved treatment for patients diagnosed with long-chain fatty acid oxidation disorders (LC-FAOD)

Categories

Industries:healthcare

Types:corporate

Keywords

long-chain fatty acid oxidation disorders LC-FAOD DOJOLVI triheptanoin FDA-approved treatment

Tech Stack

Theme:ultdo_full_patient_child

Plugins:stop-user-enumeration

Color Palette

Primary#282e3c

Accent#f59e0b

Background#ffffff

Secondary 1#007bff

Secondary 2#00d0bc

Contact Information

Phone:+1-800-555-1234

Social Media:

Full Screenshot

DOJOLVI® (triheptanoin) for LC-FAOD - Full Screenshot

Loading...